Disclosed security · Transaction Sep 20, 2021 · Filed Oct 5, 2021 · $50,001 to $100,000
XNAS · CRSP
-0.22% · -$0.1300 · Vol 3.4M
Market closed · last close 4:00 PM ET · price as of 19:59:27 ET
CRISPR Therapeutics AG
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$57.20
Follow $CRSP
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $CRSP by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredFri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET · CRSP
MethodologyCRSP
CRISPR Therapeutics AG
Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Upper range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
66/ 100
Veridion Score
Upper range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is CRSP moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About CRISPR Therapeutics AG
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Listed since
2016
Employees
393
Country
US
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$58.00
Day high
$59.34
Day low
$55.63
Previous close
$57.33
52W high
$76.78
-25.50% from high
52W low
$44.34
40% of range
Market cap
$5.5B
EPS
$-5.7900
Beta
1.93
Shares out
96.7M
Volume
3.4M
2.19× rel vol
Avg volume
1.5M
VWAP
$56.59
Price history computed in-house
1W
+10.60%
1M
-3.87%
3M
+5.22%
1Y
-8.22%
YTD
+9.08%
SMA 50 $53.03 · above
SMA 200 $53.32 · above
52W position 40%
CRSP overview
Related filings and maps
Public disclosures
Congress activity in CRSP
Official filing ↗
Thomas R. SuozziSell
CRISPR Therapeutics Ag - Common Shares · Transaction Sep 20, 2021 · Filed Oct 5, 2021 · $50,001 to $100,000
CRSP · Transaction Jun 3, 2021 · Filed Sep 23, 2021 · $50,001 to $100,000
CRISPR Therapeutics AG - Common Shares · Transaction Jan 21, 2021 · Filed Feb 19, 2021 · $1,001 to $15,000
Federal contracts
CRSP contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CRSP in this window.
Lobbying spend
CRSP lobbying filings, year to date.
Registered lobbying filings matched to CRISPR Therapeutics AG.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CRSP in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for CRSP.
Options
Sovereign unlock shows live options positioning for CRSP.